ZYPREXA VELOTAB 10mg price in UAE

Overview

Welcome to Dwaey, specifically on ZYPREXA VELOTAB 10mg Tablets/Orodispersible page.
This medicine contains an important and useful components, as it consists of Olanzapine.
ZYPREXA VELOTAB 10mg is available in the market in concentration 10mg/Tablet and in the form of Tablets/Orodispersible.

ELI LILLY & CO LTD. is the producer of ZYPREXA VELOTAB 10mg and it is imported from UK, The most popular alternatives of ZYPREXA VELOTAB 10mg are listed downward .

Mode Of Action

Olanzapine is an atypical antipsychotic with affinity for serotonin 5-HT2A/2C, dopamine, muscarinic M1-M5, histamine H1 and adrenergic ?1 receptors.

Indication

Schizophrenia
Bipolar disorder
Agitation
Mania

Precaution

Patient w/ cerebrovascular disease or conditions predisposing to hypotension, benign prostatic hyperplasia, paralytic ileus, DM, Parkinson's disease, history of blood dyscrasias, bone marrow depression, hypereosinophilic disorders, myeloproliferative disease, history of seizures or conditions that lower the seizure threshold. IM: Acute MI, unstable angina, severe hypotension or bradycardia, sick sinus syndrome, recent heart surgery. Elderly w/ dementia-related psychosis. Hepatic and renal impairment. Pregnancy and lactation. Patient Counselling This drug may cause somnolence and dizziness, if affected, avoid driving and operating machinery. Avoid cigarette smoking. Monitoring Parameters Monitor BP, pulse and resp rate for at least 4 hr after IM inj. Clinical monitoring for hyperglycaemia, plasma lipids and wt. Lactation: Drug enters breast milk; not recommended

Side Effects

>10% Orthostatic hypotension (>20%)
Weight gain
dose dependent (5-40%)
Hypertriglyceridemia (<39%)
Hypercholesterolemia (<39%)
Somnolence
dose dependent (6-39%)
Extrapyramidal symptoms (EPS)
dose dependent (15-32%)
Xerostomia (9-22%)
Weakness (2-20%)
Dizziness (4-18%)
Accidental injury (12%)
Insomnia (12%)
Elevated alanine aminotransferase (ALT) level (5-12%)
Constipation (9-11%)
Dyspepsia (7-11%)
Hyperprolactinemia (30%)
Hyperglycemia (12.8%) 1-10% Hypotension (2%)
Postural hypotension (1%)
Tremor (1%)
Asthenia (2%)
Akathisia reactions (2%)
Parkinsonism reactions (4%) <1% Syncope
Sudden cardiac death
Hyperglycemia
Diabetic coma with ketoacidosis
Diabetic ketoacidosis
Acute hemorrhagic pancreatitis
Venous thromboembolism
Immune hypersensitivity reaction
Cerebrovascular disease
Seizure
status epilepticus
Suicidal intent
Pulmonary embolism
Death
Neuroleptic malignant syndrome (NMS)
Tardive dyskinesia Potentially Fatal: Exacerbation of preexisting diabetes sometimes leading to ketoacidosis. Neuroleptic malignant syndrome.

Contra indication

Angle-closure glaucoma; lactation. IM: History of CVS disease, heart surgery.

Pregnancy and lactation

Pregnancy category: C

Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks

Interaction

Olanzapine may antagonise the effects of levodopa and dopamine agonists. Drugs that induce CYP1A2 or glucuronyl transferase enzymes e.g. omeprazole and rifampicin, may increase olanzapine clearance. Inhibitors of CYP1A2 may potentially inhibit olanzapine elimination. Carbamazepine may increase the clearance of olanzapine. Concomitant admin of activated charcoal reduced the oral bioavailability of olanzapine by 50-60%. Caution should be taken when olanzapine is administered with centrally acting drugs and alcohol.